Damora Therapeutics, Inc.
$26.43
▲
0.04%
2026-04-21 06:27:01
www.damoratx.com
NCM: DMRA
Explore Damora Therapeutics, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$1.6 B
Current Price
$26.43
52W High / Low
$29.22 / $16.5
Stock P/E
—
Book Value
$-110.11
Dividend Yield
—
ROCE
-87.69%
ROE
-1.64%
Face Value
—
EPS
$-3.98
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
7
Beta
1.6
Debt / Equity
0.03
Current Ratio
12.98
Quick Ratio
12.98
Forward P/E
—
Price / Sales
—
Enterprise Value
$1.72 B
EV / EBITDA
-46.95
EV / Revenue
—
Rating
None
Target Price
$46.2
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Silexion Therapeutics Corp | $1.08 | — | $3.63 M | — | -260.98% | 1718.9% | $22.36 / $0.97 | $0.83 |
| 2. | Surrozen, Inc. | $32.25 | — | $362.52 M | — | -47.4% | 231.45% | $33.22 / $5.9 | $-19.21 |
| 3. | Nuvectis Pharma, Inc. | $8.33 | — | $235.78 M | — | -149.75% | -1.88% | $11.52 / $5.55 | $0.72 |
| 4. | Galmed Pharmaceuticals Ltd. | $0.75 | — | $4.81 M | — | -38.45% | -64.21% | $2.68 / $0.41 | $3.49 |
| 5. | Aprea Therapeutics, Inc. | $0.98 | — | $11.45 M | — | -100.49% | -74.58% | $2.22 / $0.55 | $1.52 |
| 6. | CervoMed Inc. | $3.97 | — | $36.76 M | — | -155.27% | -93.92% | $13.13 / $3.51 | $1.97 |
| 7. | Inhibrx Biosciences, Inc. | $82.39 | — | $1.29 B | — | -119.83% | -1.98% | $94.56 / $10.84 | $0.55 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -201.7 M | -3.16 M | -3.42 M | -2.6 M | -7.1 M | — |
| Net Profit | -200.74 M | -3.13 M | -3.44 M | -2.53 M | -6.74 M | — |
| EPS in Rs | -3.33 | -0.05 | -0.06 | -0.04 | -0.11 | -3.39 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -210.87 M | -21.29 M | -36.46 M | -61.21 M |
| Net Profit | -209.84 M | -21.44 M | -38.35 M | -61.62 M |
| EPS in Rs | -3.48 | -0.36 | -0.64 | -1.02 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 260.53 M | 17.13 M | 38.23 M | 73.19 M |
| Total Liabilities | 20.15 M | 1.3 M | 5.9 M | 11.44 M |
| Equity | 240.38 M | 15.83 M | 32.33 M | 61.75 M |
| Current Assets | 260.42 M | 16.84 M | 36.77 M | 63.91 M |
| Current Liabilities | 20.07 M | 1.2 M | 5.83 M | 11.11 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -6.73 M | -18.62 M | -36.91 M | -42.93 M |
| Investing CF | -17.37 M | 11.65 M | 22.33 M | 12.38 M |
| Financing CF | 266.84 M | 0 M | 2.88 M | 0.51 M |
| Free CF | -6.73 M | -18.62 M | -36.91 M | -43.13 M |
| Capex | — | — | — | -0.2 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | 44.1% | 37.77% | — | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2024-08-30 | 1:0.04 |